ty -jour t1-回顾性TBNET评估LineZolid安全性，可耐受性结核病的耐受性和功效JF-欧洲呼吸杂志JO -EUR RESSIR J SP -387 LP -387 LP -393 DO -10.1183/109031936.00936.00936.00936.00936.00959509 VL -34 IS -2 -24Migliori，G。B. Au -Eker，B。Au -Richardson，M。D. au -Sotgiu，G。Au -Zellweger，J -P。Au -Skrahina，A.Au -Ortmann，J.Au -Girardi，E.Au -Hoffmann，H。Au -au -Besozzi -au au -au -au -bevilacqua，N.Lange，C.A2 - ，Y1-2009/08/01 UR -http：//www.qdcxjkg.com/content/34/2/2/387.abstract n2-使用LineZolid用于治疗多药耐药者（MDR）的患者/广泛耐药（XDR） - 结核病（TB）病例，尽管缺乏有关其安全性，耐受性和功效的临床数据。我们进行了一项回顾性，非随机，无盲的观察性研究，评估了600 mg Q.D的LineZolid的安全性和耐受性。或B.I.D.在四个欧洲国家的MDR/XDR-TB治疗中。疗效评估比较了45个lineZolid处理的终点与110个linezolid非拘留案例的终点。在195名MDR/XDR-TB患者中，有85例用LineZolid治疗平均221天。在其中，有35个（41.2％）中有85个经历了归因于LineZolid（贫血，血小板减少症和/或多神经病）的重大副作用，需要在27例（77％）病例中停用。 Most side-effects occurred after 60 days of treatment. Twice-daily administration produced more major side-effects than once-daily dosing (p = 0.0004), with no difference in efficacy found. Outcomes were similar in patients treated with/without linezolid (p = 0.8), although linezolid-treated cases had more first-line (p = 0.002) and second-line (p = 0.02) drug resistance and a higher number of previous treatment regimens (4.5 versus 2.3; p = 0.07). Linezolid 600 mg q.d. added to an individualised multidrug regimen may improve the chance of bacteriological conversion, providing a better chance of treatment success in only the most complicated MDR/XDR-TB cases. Its safety profile does not warrant use in cases for which there are other, safer, alternatives. ER -